Pharmaceutical firm SSY Group (HKG:2005) obtained production and registration approval for the Epinephrine Hydrochloride Injection from China's National Medical Products Administration after passing the regulator's consistency evaluation, a Friday filing with the Hong Kong bourse said.
The Epinephrine Hydrochloride injection is the main rescue drug for cardiopulmonary resuscitation in cardiac arrest and can be used to treat severe dyspnea caused by bronchospasm, rapid relief of anaphylaxis, and prolongation of action time for infiltration anesthesia drugs.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.